

iCANPOD

Training the Next Leaders in Precision Cancer Medicine


Opening Event

Postdoctoral Program
in Precision Cancer Medicine

Wednesday 26.11.2025

Lecture Hall 1, Biomedicum 1

Faculty of Medicine, University of Helsinki



Program Highlights

12:30–12:35 Welcome & Opening Remarks

12:35–13:30 Keynote – Prof. Johan Hartman

13:30–13:50 Biobreak

13:50–15:00 Postdoctoral Presentations

15:00–15:30 Transition & Coffee


15:30–17:00 Poster Session & Networking

instagram page



@icandoc_pod

iCANPOD



Keynote
Speaker



Johan Hartman
Dept of Oncology
and Pathology Karolinska
Institute and Karolinska University Hospital

“Pathology in the era of precision medicine”

iCANPOD

Postdoctoral Researchers' Presentations

13:50- 14:00

“What is iCANPOD?”

Piia-Riitta Karhemo, iCANDOC Scientific Coordinator

14:00 – 14:15

“DORSSAA: Drug-target interactOmics Resource based on Stability/Solubility Alteration Assay”.

Ehsan Zangene, Department of Biochemistry and Developmental Biology (Medicum), Faculty of Medicine, University of Helsinki

14:15 – 14:30

“Lumping or splitting? Outcome prediction and subtyping in high-grade serous carcinoma”.

Anna Laury, Research Programs Unit, Faculty of Medicine, University of Helsinki

14:30– 14:45

“Multi-Layer Profiling of Neuronal Differentiation and Its Dysregulation in Neuroblastoma”.

Dicle Malaymar Pinar, HiLIFE and Institute of Biotechnology, University of Helsinki

14:45- 15:00

“Reticular adhesions shape our understanding on cancer cell migration”.

Laura Hakanpää, HiLIFE and Institute of Biotechnology, University of Helsinki.

iCANPOD

15:00 – 15:30

Coffee, snack, mingling, transition to posters

15:30 – 17:00

Poster Session & Networking

Ruoyu Cheng	Nanoparticles for intracellular drug delivery
Milos Gojkovic	Hunting for blood-based biomarkers for immunotherapy optimization in lung cancer
Surachet Imlimthan	Radiopharmaceutical Chemistry and In Vivo Nuclear Imaging Services at University of Helsinki
Piia-Riitta Karhemo	Molecular profiling and ex vivo drug screening of soft tissue sarcomas
Elena Kremneva	Precision tumor-on-chip model for personalized drug efficacy and immune cell delivery assessment
Romika Kumari	Integrative Molecular Tumor Board (iMTB): A decision-support tool for precision cancer medicine in iCAN
Sara Kuusela	Functional precision medicine reveals drug vulnerabilities in pediatric sarcoma
Essi Laajala	Supervised learning for the identification of AML cells in single-cell RNA sequencing data
Anna Laury	KRAS amplification in tubo-ovarian high-grade serous carcinoma
Dicle Malaymar Pinar	Multi-layer profiling of neuronal differentiation and its dysregulation in neuroblastoma
Minttu Marttila	Novel variants in lung cancer
Pauliina Munne	Soft matrix promotes immunosuppression in tumor-resident immune cells via COX–FGF2 signaling
Otto Mäkelä	Renal differentiation and safe regeneration in spiny mouse (<i>Acomys</i>)
Karita Peltonen	Tumor-specific T-cell repertoire among tumor-infiltrated CD8 ⁺ T cells and their phenotypic and functional features
Anne Pink	Integrin inhibitor SHARPIN regulates vascular permeability by controlling tension-induced endothelial cell adhesion complexes
Natalie Aparecida Rodrigues Fernandes	Effect of $\alpha 5$ integrin and fibronectin on monocyte fate in HNSCC
Ehsan Zangene	DORSSAA: Drug-target interactOmics resource based on Stability/Solubility Alteration Assay

iCANPOD